Last reviewed · How we verify
ESN364
At a glance
| Generic name | ESN364 |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- COVID-19
- Blood alkaline phosphatase increased
- Urinary tract infection
- Alanine aminotransferase increased
- Gamma-glutamyltransferase increased
- Nasopharyngitis
- Arthritis
- Back pain
- Palpitations
- Hot flush
- Diarrhoea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESN364 CI brief — competitive landscape report
- ESN364 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI